Shares of diagnostics company Immucor ( BLUD) rose modestly after the company boosted expectations for its full-year results.

The Norcross, Ga.-based company recorded fiscal second-quarter earnings of $14.1 million, or 20 cents a share, compared with $8.1 million, or 11 cents a share, a year ago. Analysts surveyed by Thomson First Call were expecting the company to earn 18 cents a share.

Quarterly revenue reached $54.4 million, up 24% from the year-ago period, thanks partly to price increases and warranty and service revenue, the company said in a press release after the close of trading Wednesday. Analysts were expecting revenue of $51.4 million.

Immucor raised guidance for the fiscal year ending May 2007. The company expects to report revenue of between $214 million and $218 million, compared with its previous guidance of $204 million to $212 million.

While Immucor expects that sales of its instruments in the next two quarters will be higher than in the second quarter, the company expects cost of sales on the devices to increase.

As a result of a recent supply agreement with Quest Diagnostics ( DGX), the company expects to ship up to 27 of its Galileo devices to Quest by the end of the fiscal year, Immucor says.

Shares gained 53 cents, or 1.8%, to $30.65 early Thursday.